Release Date: March 19, 2025
Expiration Date: April 30, 2025
Activity Overview
This educational activity is an archive of the live virtual presentation held on February 15, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, gastroenterologists, and hepatologists who are interested in the treatment of gastrointestinal (GI) cancers. Nurse practitioners, physician assistants, nurses, pathologists, pharmacists, and other health care professionals involved in the treatment and management of patients with GI cancers are invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine evolving strategies to personalize care in gastrointestinal cancers through molecular and genomic analysis
- Discuss multidisciplinary strategies for integrating multimodal approaches to personalize care in gastrointestinal cancers
- Evaluate evolving data in gastrointestinal cancer care
- Assess best practices in the prevention, management, and mitigation of TRAEs in gastrointestinal cancers
E. Gabriela Chiorean, MD
Professor, Clinical Research Division, Fred Hutch
Professor, Medicine, University of Washington School of Medicine
Clinical Director, Gastrointestinal Medical Oncology, Fred Hutch
Clinical Research Director, Gastrointestinal Medical Oncology, UW Medicine
Fred Hutchinson Cancer Center
Seattle, WA
Disclosures: Grant/Research Support: Affini-T Therapeutics, BioAtla, Biosplice Therapeutics, Bristol Myers Squibb, Erasca, Genentech, Gilead Sciences, Novartis; Adviser: Aadi Bioscience, BPGBio, Bristol Myers Squibb, Merus, Pfizer, Purple Biotech, Regeneron, Takeda.
John L. Marshall, MD
Professor of Medicine and Oncology
Chief, Hematology and Oncology
Director, Ruesch Center for the Cure of Gastrointestinal Cancers
Georgetown Lombardi Comprehensive Cancer Center
Washington, DC
Disclosures: Consultant: Astellas, AstraZeneca, Bayer, Merck, Pfizer, Taiho Oncology, Takeda.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
